Welcome to our dedicated page for Pulse Biosciences news (Ticker: PLSE), a resource for investors and traders seeking the latest updates and insights on Pulse Biosciences stock.
Pulse Biosciences, Inc. (Nasdaq: PLSE) generates frequent news as it advances its proprietary nPulse nanosecond pulsed field ablation (nsPFA) technology across cardiac and soft tissue applications. The company’s updates focus on clinical trial progress, regulatory milestones, scientific data presentations and early commercial activity for its nsPFA-based systems.
Investors and clinicians following PLSE news will see announcements on key atrial fibrillation programs, including the nPulse Cardiac Surgical System and the nPulse Cardiac Catheter Ablation System. Company releases describe IDE approvals from the U.S. Food and Drug Administration, enrollment of patients in the NANOCLAMP AF and NANOPULSE-AF studies, and feasibility results from European centers using surgical and catheter-based nsPFA devices. Late-breaking data presentations at major cardiology and cardiothoracic surgery meetings are also highlighted.
News flow also covers soft tissue ablation initiatives, such as the nPulse Vybrance Percutaneous Electrode System for benign thyroid nodules and research collaborations with academic centers on benign and malignant thyroid tumors. Pulse Biosciences reports publication of first-in-human thyroid data, IDE approvals for thyroid studies, and progress in multi-center trials like PRECISE-BTN.
In addition, PLSE news includes quarterly business updates and financial results, inducement equity grants under Nasdaq rules, and participation in healthcare investor conferences. These items provide context on the company’s operating plans, clinical strategy and capital markets activity. For readers tracking the development of nsPFA technology in atrial fibrillation and thyroid or other soft tissue indications, the Pulse Biosciences news page offers a consolidated view of company disclosures, clinical milestones and corporate events over time.
Pulse Biosciences (Nasdaq: PLSE) announced its nPulse Vybrance system will be featured in a podium presentation and a product theatre at the North American Society for Interventional Thyroidology meeting, March 6-7, 2026 in Portland.
Presentations include an interim feasibility report reviewing long-term follow-up up to 22 months for patients treated with nsPFA for benign, symptomatic thyroid nodules; a roundtable will discuss mechanism, results, and case studies.
Pulse Biosciences (Nasdaq: PLSE) announced inducement equity awards approved February 18, 2026 under its 2017 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The Compensation Committee granted stock options to two new employees to purchase up to 19,000 shares at an exercise price of $25.46 per share, equal to the February 18, 2026 closing price, vesting time-based over four years with 1/4 vesting annually, subject to continued employment and plan terms.
Pulse Biosciences (Nasdaq: PLSE) will present at the 46th Annual TD Cowen Healthcare Conference in Boston on Wednesday, March 4, 2026 at 1:10 pm ET. Management will deliver a live presentation and a webcast will be available.
A recorded webcast will be posted on the company’s investor Events Calendar and Presentations page at http://investors.pulsebiosciences.com/.
Pulse Biosciences (Nasdaq: PLSE) reported Q4 and full-year 2025 results and business updates on Feb 19, 2026. Key clinical milestones include FDA IDE approvals to start pivotal studies for the nPulse Cardiac Catheter System and surgical nPulse Cardiac Surgery System, and 100% 6‑month procedural success in a feasibility AF study.
Financials: Q4 revenue $264k, FY2025 revenue $350k, GAAP net loss Q4 ($17.4M) and FY ($72.8M); cash $80.7M at year-end.
Pulse Biosciences (Nasdaq: PLSE) presented late-breaking first-in-human feasibility data for the nPulse Cardiac Catheter at the AF Symposium on February 6, 2026. Key findings: 100% procedural success at 6 months (75/75), 96% at 12 months (45/47), average 16.1 applications, procedure time 65 ± 28 minutes, fluoroscopy 9.8 ± 5.8 minutes, left atrial dwell 21.0 ± 13.3 minutes, and 1.3% SAE rate (2/150). The study has treated 165 patients to date across nine European investigators and continues into a pivotal IDE study.
Pulse Biosciences (Nasdaq: PLSE) will report fourth quarter and full year 2025 business updates and financial results after market close on February 19, 2026. Management will host a conference call at 1:30 PM PT / 4:30 PM ET.
Investors can join by phone (U.S. 1-800-715-9871; international 1-646-307-1963, Conference ID 7647402) or via a live and recorded webcast on the company investor website.
Pulse Biosciences (Nasdaq: PLSE) will feature its nPulse Cardiac Catheter at the 31st Annual AF Symposium (Feb 5-7, 2026) in Boston, including a late-breaking clinical science session, a live case transmission, and a poster showing preclinical lesion-depth data.
Presentations include 6‑ and 12‑month follow-up from a 150‑patient feasibility experience at three European centers and a live broadcast from Na Homolce Hospital demonstrating EnSiteX™ 3D mapping integration.
Pulse Biosciences (Nasdaq: PLSE) announced that late‑breaking data from its nPulse Cardiac Catheter Ablation System first‑in‑human feasibility study in Europe was accepted for presentation at the 31st Annual AF Symposium 2026 in February.
The presentation, by Vivek Reddy, MD, will include 6‑month and 12‑month follow‑up data from the study. The company said it will provide presentation times in late January.
Pulse Biosciences (Nasdaq: PLSE) will present at the 44th Annual J.P. Morgan 2026 Healthcare Conference in San Francisco. Management is scheduled to present on Wednesday, January 14, 2026 at 3:45pm PT. A live and recorded webcast will be available on the company’s investor website under the Events Calendar and Presentations page. The company leverages its nPulse™ platform using Nanosecond Pulsed Field Ablation™ (nsPFA™) energy.
Pulse Biosciences (Nasdaq: PLSE) announced that its Compensation Committee approved inducement equity awards to two new employees on December 15, 2025 under the 2017 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards grant options to purchase an aggregate of 3,400 shares at an exercise price of $14.13 per share (equal to the closing price on December 15, 2025). Options vest on a four-year, time-based schedule with 1/4 vesting annually, subject to continued employment, and are governed by the inducement plan and award agreements.